Spots Global Cancer Trial Database for ipilimumab
Every month we try and update this database with for ipilimumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | NCT02982486 | Soft Tissue Sar... Bone Sarcoma Chondrosarcoma Gastrointestina... Ewing's Tumor M... Ewing's Tumor R... Osteosarcoma Desmoplastic Sm... | Ipilimumab Nivolumab | 18 Years - | Assaf-Harofeh Medical Center | |
| Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | NCT03816358 | Pancreatic Aden... Stage II Pancre... Stage III Pancr... Stage IV Pancre... | Anetumab Ravtan... Biopsy Biospecimen Col... Gemcitabine Hyd... Ipilimumab Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | NCT02032810 | Melanoma Skin Cancer | Panobinostat Ipilimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | NCT02453620 | Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Invasive Breast... Malignant Solid... | Biopsy Blood Sample Bone Scan Computed Tomogr... Entinostat Ipilimumab Nivolumab Pharmacogenomic... Pharmacological... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | NCT03104439 | Microsatellite ... Pancreatic Canc... MSI High Colore... | Nivolumab Ipilimumab Radiation Thera... | 18 Years - | Massachusetts General Hospital | |
| A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | NCT02982486 | Soft Tissue Sar... Bone Sarcoma Chondrosarcoma Gastrointestina... Ewing's Tumor M... Ewing's Tumor R... Osteosarcoma Desmoplastic Sm... | Ipilimumab Nivolumab | 18 Years - | Assaf-Harofeh Medical Center | |
| Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome | NCT03767439 | Basal Cell Nevu... | Vismodegib Nivolumab Ipilimumab | 18 Years - | Columbia University | |
| ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma | NCT03003637 | Immunotherapy Head and Neck N... | Nivolumab Ipilimumab | 18 Years - | The Netherlands Cancer Institute | |
| Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer | NCT03101566 | Biliary Tract N... | Gemcitabine Cisplatin Ipilimumab Nivolumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | NCT05498792 | Locally Advance... | CBL0137 Ipilimumab Nivolumab | 18 Years - | Fox Chase Cancer Center | |
| TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer | NCT03287674 | Metastatic Ovar... | Cyclophosphamid... Fludarabine TIL infusion Interleukin-2 Ipilimumab Nivolumab | 18 Years - 70 Years | Herlev Hospital | |
| Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | NCT01473940 | Duct Cell Adeno... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... | ipilimumab gemcitabine hyd... laboratory biom... | 18 Years - | Northwestern University | |
| Adoptive Therapy Using Antigen-Specific CD4 T-Cells | NCT02210104 | Melanoma Sarcoma | Ipilimumab Cyclophosphamid... CD4+ T cells | 18 Years - | M.D. Anderson Cancer Center | |
| Cytokine-induced Killer Study for Patients With Stage II Melanoma | NCT02498756 | Melanoma | Cytokine-induce... Ipilimumab | 18 Years - 80 Years | The First People's Hospital of Changzhou | |
| A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | NCT03999749 | Melanoma | Ipilimumab Nivolumab Tocilizumab | 18 Years - | NYU Langone Health | |
| Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma | NCT02626962 | Uveal Melanoma | ipilimumab Nivolumab | 18 Years - 99 Years | Grupo Español Multidisciplinar de Melanoma | |
| A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma | NCT03153085 | Melanoma Stage ... Melanoma Stage ... | TBI-1401(HF10) Ipilimumab | 20 Years - | Takara Bio Inc. | |
| Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | NCT04518046 | Clear-Cell Rena... | Sitravatinib Nivolumab Ipilimumab | 18 Years - | Mirati Therapeutics Inc. | |
| Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma | NCT02659540 | Melanoma | Nivolumab Ipilimumab Radiotherapy | 18 Years - | Ludwig Institute for Cancer Research | |
| Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study. | NCT03784040 | Gastric Cancer | OTSGC-A24 Nivolumab Ipilimumab | 21 Years - 99 Years | National University Hospital, Singapore | |
| Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | NCT03158129 | Stage I Lung No... Stage IA Lung N... Stage IB Lung N... Stage II Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... | Carboplatin Cisplatin Docetaxel Ipilimumab Nivolumab Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| Impact of Telemonitoring for the Management of Side Effects in Patients With Melanoma, Lung or Renal Cancer, Treated With Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy | NCT04605146 | Melanoma Lung Cancer Renal Cancer | Tele-monitoring | 18 Years - | Hospices Civils de Lyon | |
| Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | NCT03570619 | Metastatic Cast... Metastatic Canc... Solid Tumor | Nivolumab Ipilimumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab | NCT02977052 | Malignant Melan... | Ipilimumab Nivolumab Surgery Blood for PBMCs Biopsies | 18 Years - | The Netherlands Cancer Institute | |
| Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition | NCT03453892 | Metastatic Canc... | Nivolumab Pembrolizumab Radiotherapy Ipilimumab | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | NCT01708941 | Recurrent Melan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Ipilimumab Laboratory Biom... Recombinant Int... | 18 Years - | National Cancer Institute (NCI) | |
| Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | NCT03707457 | Glioblastoma Glioblastoma Mu... | Nivolumab Anti-GITR Monoc... IDO1 inhibitor ... Ipilimumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma | NCT03097939 | Nasopharyngeal ... | Ipilimumab Nivolumab | 21 Years - 80 Years | National Cancer Centre, Singapore | |
| A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer | NCT03048136 | Non-Small Cell ... | Nivolumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial | NCT03977571 | Kidney Cancer Renal Cell Carc... Synchronous Neo... | Cytoreductive n... Tissue sampling | 18 Years - | University of Aarhus | |
| Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer | NCT05219435 | Urothelial Canc... | Nivolumab Ipilimumab | 18 Years - | Spanish Oncology Genito-Urinary Group | |
| Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | NCT03914300 | Differentiated ... Follicular Vari... Poorly Differen... Refractory Diff... Refractory Thyr... Tall Cell Varia... Thyroid Gland F... Thyroid Gland O... Thyroid Gland P... | Biospecimen Col... Cabozantinib S-... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma | NCT00077532 | Melanoma (Skin) | gp100 antigen incomplete Freu... ipilimumab | 16 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | NCT02073123 | Metastatic Mela... Stage III Melan... Stage IV Melano... | Indoximod Ipilimumab Nivolumab Pembrolizumab | 18 Years - | Lumos Pharma | |
| An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers | NCT03956680 | Advanced Solid ... | BMS-986301 Nivolumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases | NCT05341349 | Clinical Stage ... Melanoma of Unk... Metastatic Mali... Metastatic Mela... Metastatic Muco... Metastatic Ocul... Pathologic Stag... | Ipilimumab Nivolumab Pembrolizumab Stereotactic Ra... Tumor Treating ... | 22 Years - | Emory University | |
| Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | NCT02403778 | Melanoma | VESANOID Ipilimumab | 18 Years - 89 Years | University of Colorado, Denver | |
| Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC | NCT04043195 | Advanced NSCLC | Nivolumab Oxaliplatin Ipilimumab | 18 Years - | University of California, San Diego | |
| Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | NCT02452281 | Melanoma | ipilimumab HSPPC-96 | 18 Years - | The University of Texas Health Science Center, Houston | |
| Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | NCT05836571 | Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Undi... | Biopsy Biospecimen Col... Cabozantinib Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | NCT01689870 | Metastatic Mela... | Anti-OX40 Ipilimumab | 18 Years - | Ludwig Institute for Cancer Research | |
| Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma | NCT02406183 | Melanoma Effects of Immu... Adverse Effect ... | Stereotactic bo... Ipilimumab | 18 Years - | University Hospital, Ghent | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | NCT02496208 | Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe... | Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma | NCT03033576 | Clinical Stage ... Clinical Stage ... Melanoma of Unk... Mucosal Melanom... Unresectable Cu... Unresectable Me... | Ipilimumab Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery | NCT03307616 | Dedifferentiate... Recurrent Dedif... Recurrent Undif... Resectable Dedi... Resectable Undi... Undifferentiate... | Ipilimumab Nivolumab Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | NCT04362839 | Advanced Colon ... Metastatic Colo... Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... | Ipilimumab Nivolumab Regorafenib | 18 Years - | City of Hope Medical Center | |
| Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | NCT00289640 | Melanoma | ipilimumab (MDX... Ipilimumab Ipilimumab | 16 Years - | Bristol-Myers Squibb | |
| Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer | NCT03989362 | Cancer | Vopratelimab Ipilimumab | 18 Years - | Jounce Therapeutics, Inc. | |
| Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma | NCT03604978 | Grade 2 Meningi... Grade 3 Meningi... Recurrent Menin... | Biospecimen Col... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab Stereotactic Ra... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC | NCT03215706 | Non-Small Cell ... | Ipilimumab Nivolumab Carboplatin Paclitaxel Pemetrexed Cisplatin | 18 Years - | Bristol-Myers Squibb | |
| Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers | NCT04270864 | Advanced Cancer | Ipilimumab Nivolumab Tilsotolimod | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | NCT03335540 | Advanced Cancer | Nivolumab Relatlimab Cabiralizumab Ipilimumab IDO1 Inhibitor Radiation Thera... | 18 Years - | Bristol-Myers Squibb | |
| A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | NCT01604889 | Melanoma | Epacadostat Placebo ipilimumab ipilimumab | 18 Years - | Incyte Corporation | |
| A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants | NCT05136677 | Mesothelioma, M... | Nivolumab Ipilimumab Pemetrexed Cisplatin Carboplatin | 18 Years - | Bristol-Myers Squibb | |
| A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung Cancer | NCT05599685 | Carcinoma, Non-... | 18 Years - | Bristol-Myers Squibb | ||
| A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | NCT03058289 | Breast Cancer Head and Neck C... Squamous Cell C... Lymphoma Pancreatic Canc... Liver Cancer Colon Cancer Lung Cancer Bile Duct Cance... Chordoma of Sac... Sarcoma | INT230-6 anti-PD-1 antib... anti-CTLA-4 ant... | 18 Years - | Intensity Therapeutics, Inc. | |
| An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy | NCT01585987 | Locally Advance... | Ipilimumab Best Supportive... | 18 Years - | Bristol-Myers Squibb | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | NCT02453620 | Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Invasive Breast... Malignant Solid... | Biopsy Blood Sample Bone Scan Computed Tomogr... Entinostat Ipilimumab Nivolumab Pharmacogenomic... Pharmacological... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | NCT03793166 | Clear Cell Rena... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Mali... Sarcomatoid Ren... Stage III Renal... Stage IV Renal ... | Biospecimen Col... Cabozantinib Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab Quality-of-Life... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) | NCT02221739 | Non-small Cell ... | Ipilimumab Radiotherapy (I... | 18 Years - 99 Years | NYU Langone Health | |
| Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases | NCT05012254 | Non Small Cell ... Brain Metastase... Lung Cancer | Ipilimumab Nivolumab Carboplatin Cisplatin Paclitaxel Pemetrexed | 18 Years - | Fundación GECP | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | NCT02311920 | Gliosarcoma Supratentorial ... | Ipilimumab Laboratory Biom... Nivolumab Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Polish Microbiome Map | NCT04169867 | Melanoma Healthy Volunte... Microbiome Metagenome Immunotherapy | Collection of s... | 18 Years - | Ardigen | |
| A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy | NCT02864251 | Non-Small-Cell ... | Nivolumab Ipilimumab Pemetrexed Cisplatin Carboplatin | 18 Years - | Bristol-Myers Squibb | |
| Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) | NCT03177239 | Renal Cell Carc... Papillary Renal... Papillary Renal... Chromophobe Ren... Sarcomatoid Ren... Xp11 Translocat... | Nivolumab Ipilimumab | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer | NCT05014776 | Pancreatic Canc... | Tadalafil Pembrolizumab Ipilimumab CRS-207 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Montreal Immune-Related Adverse Events (MIRAE) Study | NCT05139706 | Cancer Immune System D... Inflammatory Re... Autoimmune Dise... | 18 Years - 100 Years | Sir Mortimer B. Davis - Jewish General Hospital | ||
| Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients | NCT06250335 | ICB-refractory ... | Prebiotic Food-... Ipilimumab Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 | NCT01216696 | Metastatic Mela... | ipilimumab | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma | NCT01489059 | Melanoma | BMS-982470 (rec... BMS-982470 (rec... BMS-982470 (rec... BMS-982470 (rec... Ipilimumab Ipilimumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | NCT04511013 | Acral Lentigino... Clinical Stage ... Metastatic Cuta... Metastatic Mali... Metastatic Mela... Metastatic Muco... Pathologic Stag... | Binimetinib Encorafenib Ipilimumab Nivolumab | 18 Years - | SWOG Cancer Research Network | |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | NCT02419495 | Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re... | Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | NCT04039607 | Hepatocellular ... | Nivolumab Ipilimumab Sorafenib lenvatinib | 18 Years - | Bristol-Myers Squibb | |
| A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | NCT03122522 | Metastatic Mela... | ipilimumab nivolumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma | NCT05041062 | Mesothelioma Peritoneal Meso... | Nivolumab Ipilimumab | 18 Years - | University of Chicago | |
| Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy. | NCT02600143 | Melanoma Colitis | 18 Years - | University Medical Center Groningen | ||
| DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | NCT04334759 | Mesothelioma Pleural Mesothe... Malignant Pleur... | Durvalumab Standard Chemot... Ipilimumab and ... | 18 Years - | PrECOG, LLC. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
